Drug Profile

Glibenclamide - AMMTeK

Alternative Names: AMGLIDIA; Amglidia; glyburide oral suspension

Latest Information Update: 29 Nov 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AMMTeK
Developer AMMTeK; Assistance Publique Hopitaux de Paris
Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas; Vascular disorder therapies
Mechanism of Action KATP channel inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Type 2 diabetes mellitus
New Molecular Entity No

Highest Development Phases

Marketed Type 2 diabetes mellitus

Most Recent Events

25 Nov 2024 Glibenclamide - AMMTeK (Amglidia^®) licensed to Eton Pharmaceuticals in USA
25 Nov 2024 Eton Pharmaceuticals announces intention to submit NDA to the US FDA for Type 2 diabetes mellitus in 2026
25 Nov 2024 Eton plans to hold a meeting with the US FDA in the first quarter of 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com